NEW HAVEN, Conn., July 15, 2026
Veradermics announced positive topline results from its open-label Phase 2 Study 207 evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in women with mild-to-moderate female pattern hair loss. The investigational therapy achieved rapid and consistent hair growth, with the majority of participants reporting visible improvement by Month 2 and nearly 90% reporting improved or much improved hair coverage after six months of treatment. The company believes VDPHL01 has the potential to become the first FDA-approved oral prescription treatment for female pattern hair loss.
Study 207 Demonstrates Rapid and Consistent Hair Growth
Women receiving VDPHL01 4.5 mg once daily or 4.5 mg twice daily experienced clinically meaningful improvements in hair density over six months. Mean increases in non-vellus target area hair count reached 22.7 hairs/cm² in the once-daily group and 23.3 hairs/cm² in the twice-daily group. Patient-reported outcomes using the Androgenetic Alopecia Impact Rating Scale (AAIRS) showed that 88.9% of participants receiving once-daily dosing and 90.0% receiving twice-daily dosing reported their hair coverage as “improved” or “much improved” at Month 6. Investigators similarly observed improvements in 100% of once-daily participants and 90% of twice-daily participants, with visible benefits appearing as early as Month 2.
Favorable Safety Profile Supports Continued Clinical Development
VDPHL01 demonstrated a favorable safety and tolerability profile throughout the six-month study. No treatment-related serious adverse events (SAEs) or adverse events of special interest involving cardiac safety were reported. The safety findings were consistent with previous VDPHL01 clinical studies, supporting the extended-release formulation’s goal of maintaining effective minoxidil exposure while reducing peak drug concentrations associated with cardiovascular side effects.
Advertisement
Registration-Directed Phase 2/3 Study 306 Continues Enrollment
Veradermics is advancing VDPHL01 through a comprehensive late-stage development program for both female and male pattern hair loss. The company is actively enrolling patients in Study 306, its registration-directed Phase 2/3 clinical trial evaluating women with pattern hair loss, with topline results expected during the first half of 2027. In parallel, Veradermics previously reported positive topline results from the male Phase 2/3 Study 302 and expects topline data from the second pivotal male Study 304 during the second half of 2026. If approved, VDPHL01 could become the only FDA-approved oral non-hormonal therapy for both women and men with pattern hair loss, addressing a significant unmet medical need affecting an estimated 80 million Americans.
Source: Veradermics press release
